Citation Impact
Citing Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
2017 Standout
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
2016
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
2017
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
2018
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
2018
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Applications of machine learning in drug discovery and development
2019 Standout
Immune checkpoint inhibitors: recent progress and potential biomarkers
2018 Standout
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab
2016
Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic
2018
Works of James Sun being referenced
Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA).
2016
Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP).
2016
Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in BRCA1 or BRCA2 are biologically similar and sensitive to PARP inhibition
2015
Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.
2016
Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.
2016